Biotechnology

Jade Biosciences

Jade Biosciences Issues 10 Million Shares to Raise $150 Million

Jade Biosciences Announces First Dose of Jade201 in Phase I Trial

Jade Biosciences released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5734 (forecast USD -0.4775)

BTIG Analyst Maintains Buy Rating on Jade Biosciences

Jade Biosciences released FY2025 annual earnings on March 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.1931 (forecast USD -2.9542)

Jade Biosciences released FY2025 Q4 earnings on March 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4953 (forecast USD -0.4685)

Jade Biosciences released FY2024 Q3 earnings on November 13, 2025 (EST), with actual revenue of USD 0 and EPS of USD -5.3452

Jade Biosciences released FY2025 9 Months earnings on November 13 (EST), actual revenue USD 0, actual EPS USD -13.4417

Jade Biosciences released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4822 (forecast USD -0.67)

Harrison covers healthcare stocks, Jade Biosciences rated Strong Buy

Jade Biosciences released FY2025 Semi-Annual earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -3.9713

Jade Biosciences released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.8635 (forecast USD -0.48)

Jade Biosciences Announces Participation in Investor Events

Jade Biosciences Plans JADE101 Clinical Trial

Jade Biosciences to unveil JADE101 preclinical research findings at the European Renal Association Congress

Jade Biosciences released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -12.096 (forecast USD -2.05)

Jade Biosciences Completes Merger with Aerovate

Jade Biosciences released FY2024 Annual Earnings on March 25 Post-Market (EST), Actual Revenue USD 0, Actual EPS USD -29.7759

VS MEDIA

Big Tree Cloud

Tianci

Fold

Pop Culture

ChowChow Cloud

Autozi Internet Tech Global

Green Circle Decarbonize Tech

Hitek Global Inc.

JBIO

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | JBIO Stock News

StockTitan

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | JBIO Stock News

Jade Bios priced a follow-on public offering of 10 million shares at $15.00 per share, raising approximately $140.3 million in net proceeds. The company has a 30-day option to sell an additional 1.5 million shares. Net proceeds will fund clinical trials, R&D, manufacturing, and general corporate purposes. The transaction is expected to close on June 5, 2026.

TradingView

Jade Bios prices $150M follow-on offering, 10M shares at $15; nets ~$140.3M

EWTX

PRAX

IDYA

Wedbush adjusted analyst ratings for four biotech firms: Praxis (PRAX) price target cut to $162 after POWER1 trial miss; IDEAYA (IDYA) and Edgewise (EWTX) retain Outperform ratings with targets of $58 and $52 respectively, following positive OptimUM-02 data and a $1.55B Servier deal; Jade Biosciences (JBIO) target raised to $45 on strong JADE101 Phase 1 data.

rttnews

Edgewise Therapeutics

Praxis Precision Medicines

Ideaya Biosciences

Wedbush Analyst Ratings On PRAX, IDYA, EWTX, JADE

Jade Biosciences priced a public offering of 10 million shares at $15.00 per share, raising $150 million in gross proceeds. The company intends to use the funds for clinical trials, R&D, and general corporate purposes. Underwriters include Jefferies, TD Cowen, and UBS. The offering is expected to close on June 5, 2026. Following the announcement, Jade's stock declined, closing Wednesday at $17.59 and trading down 7.02% in overnight markets.

nasdaq

Jefferies Financial

Toronto Dominion Bank

UBS Group AG

Nasdaq

Jade Biosciences Prices $150 Mln Offering Of Shares At $15.00/shr; Stock Down

Jade Biosciences Announces Pricing of Public Offering of Common Stock | JBIO Stock News

Jade Biosciences Announces Pricing of Public Offering of Common Stock | JBIO Stock News

Jade Biosciences reported positive interim Phase I results for JADE101, an investigational anti-APRIL monoclonal antibody for IgAN. In a trial of 32 healthy volunteers, JADE101 demonstrated rapid, deep, and durable IgA reductions (approx. 70%) with favorable tolerability and no serious adverse events. The drug showed extended half-life and potential for every-12-week dosing. Jade CEO Tom Frohlich described it as potentially best-in-class. An ongoing Phase II JUNIPER trial is enrolling patients, with interim data expected in 2027, followed by a planned Phase III trial.

WorldPharmaceuticals

Shutterstock

Jade reports interim Phase I results of JADE101 for IgAN

Jade Biosciences(JBIO.US)

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | JBIO Stock News

Jade Bios prices $150M follow-on offering, 10M shares at $15; nets ~$140.3M

Wedbush Analyst Ratings On PRAX, IDYA, EWTX, JADE

Jade Biosciences Prices $150 Mln Offering Of Shares At $15.00/shr; Stock Down

Jade Biosciences Announces Pricing of Public Offering of Common Stock | JBIO Stock News

Jade reports interim Phase I results of JADE101 for IgAN